Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Jennifer A. Regan; Yun Cao; Melanie C. Dispenza; Shuo Ma; Leo I. Gordon; Adam M. Petrich; Bruce S. Bochner

doi:10.1016/j.jaci.2017.03.013

Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Jennifer A. Regan, Yun Cao, Melanie C. Dispenza, Shuo Ma, Leo I. Gordon, Adam M. Petrich^*, Bruce S. Bochner

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Original language	English (US)
Pages (from-to)	875-879.e1
Journal	Journal of Allergy and Clinical Immunology
Volume	140
Issue number	3
DOIs	https://doi.org/10.1016/j.jaci.2017.03.013
State	Published - Sep 2017

ASJC Scopus subject areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jaci.2017.03.013

Cite this

Regan, J. A., Cao, Y., Dispenza, M. C., Ma, S., Gordon, L. I., Petrich, A. M., & Bochner, B. S. (2017). Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. Journal of Allergy and Clinical Immunology, 140(3), 875-879.e1. https://doi.org/10.1016/j.jaci.2017.03.013

@article{bc597d43d7154d71b1958c41711cbd40,

title = "Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity",

author = "Regan, {Jennifer A.} and Yun Cao and Dispenza, {Melanie C.} and Shuo Ma and Gordon, {Leo I.} and Petrich, {Adam M.} and Bochner, {Bruce S.}",

year = "2017",

month = sep,

doi = "10.1016/j.jaci.2017.03.013",

language = "English (US)",

volume = "140",

pages = "875--879.e1",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "3",

}

Regan, JA, Cao, Y, Dispenza, MC, Ma, S , Gordon, LI, Petrich, AM & Bochner, BS 2017, 'Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity', Journal of Allergy and Clinical Immunology, vol. 140, no. 3, pp. 875-879.e1. https://doi.org/10.1016/j.jaci.2017.03.013

Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. / Regan, Jennifer A.; Cao, Yun; Dispenza, Melanie C. et al.
In: Journal of Allergy and Clinical Immunology, Vol. 140, No. 3, 09.2017, p. 875-879.e1.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

AU - Regan, Jennifer A.

AU - Cao, Yun

AU - Dispenza, Melanie C.

AU - Ma, Shuo

AU - Gordon, Leo I.

AU - Petrich, Adam M.

AU - Bochner, Bruce S.

PY - 2017/9

Y1 - 2017/9

UR - http://www.scopus.com/inward/record.url?scp=85018674480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018674480&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2017.03.013

DO - 10.1016/j.jaci.2017.03.013

M3 - Article

C2 - 28389390

AN - SCOPUS:85018674480

SN - 0091-6749

VL - 140

SP - 875-879.e1

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 3

ER -

Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this